Association of depression and suicidal behaviour reporting with HIV integrase inhibitors: a global pharmacovigilance study.
Laure-Hélène PrétaTomasz ChroboczekJean-Marc TreluyerLaurent ChouchanaPublished in: The Journal of antimicrobial chemotherapy (2023)
Our findings suggest that depression and suicidality are adverse drug reactions of all INSTI agents, especially dolutegravir, which may occur within the first months of therapy.